Aulos Bioscience is an innovative company in the field of immuno-oncology, which focuses on using the body's immune system to fight cancer. The company is pioneering the development of IL-2 (Interleukin-2) therapeutics, a type of treatment that aims to boost the immune system's ability to combat cancer cells. Their main product, AU-007, is a monoclonal antibody designed using advanced computational methods. This product is unique because it selectively targets a specific part of IL-2, which helps activate the immune system more effectively against tumors.

Aulos Bioscience primarily serves patients battling various forms of cancer. The company operates in the biopharmaceutical market, which involves the development and commercialization of drugs derived from biological sources. Their business model revolves around research and development (R&D) of new cancer therapies, conducting clinical trials to prove their effectiveness and safety, and eventually bringing these therapies to market.

The company makes money through a combination of funding from investors, partnerships with other biotech firms, and potentially, future sales of their approved therapies. Currently, Aulos is in the clinical trial phase, specifically in Phase 2 of their Phase 1/2 clinical program for AU-007. This phase is crucial for demonstrating the safety and efficacy of their product before it can be approved for wider use.

Aulos Bioscience is driven by a strong commitment to scientific rigor and a mission to extend the lives of cancer patients. Their approach is characterized by the use of computational design to create highly specific and effective treatments, which they believe will change the landscape of cancer care.

Keywords: Immuno-oncology, IL-2 therapeutics, cancer treatment, monoclonal antibody, AU-007, computational design, biopharmaceutical, clinical trials, immune activation, cancer care innovation.